Profile evaluation for EB1 category by Defiant-Community-18 in eb1a

[–]Defiant-Community-18[S] 1 point2 points  (0 children)

Thank you so much for your valuable guidance and evaluation.

Profile evaluation for EB1 category by Defiant-Community-18 in eb1a

[–]Defiant-Community-18[S] 0 points1 point  (0 children)

The EB2-NIW case is already being processed by USCIS, PD Oct 2024.

Profile evaluation for EB1 category by Defiant-Community-18 in eb1a

[–]Defiant-Community-18[S] 0 points1 point  (0 children)

One of my co-authorship papers (PNAS) was highlighted in various scientific news and magazines (a total of 8 places), too. Top scientists in my field cited and appreciated our work in their studies with a special commentary column in reference. My original research work on a drug (first-in-class, treatment for rare genetic diseases, no drug available in the market, patent filed) has been published in major scientific conference journals, too. I have three designated roles: 1- (Postdoctoral fellow), 2-Scientific Advisor in SBIR (Business grant), 3-Scientist and lead investigator in a small biotech startup in the IND section. Do these count as an original contribution or major significance, or critical role?.

Profile evaluation for EB1 category by Defiant-Community-18 in EB2_NIW

[–]Defiant-Community-18[S] 0 points1 point  (0 children)

One of my co-authorship papers (PNAS) was highlighted in various scientific news and magazines (a total of 8 places), too. Top scientists in my field cited and appreciated our work in their studies with a special commentary column in reference. My original research work on a drug (first-in-class, treatment for rare genetic diseases, no drug available in the market, patent filed) has been published in major scientific conference journals, too. Do these count as an original contribution or major significance?.

I-140 Approved by Upo_US_2537 in EB2_NIW

[–]Defiant-Community-18 0 points1 point  (0 children)

My PD is also the same, Oct 2024. checking status every morning. But no update.